159 related articles for article (PubMed ID: 28736944)
1. Short-term acipimox treatment is associated with decreased cardiac parasympathetic modulation.
Vestergaard ET; Cichosz SL; Møller N; Jørgensen JOL; Fleischer J
Br J Clin Pharmacol; 2017 Dec; 83(12):2671-2677. PubMed ID: 28736944
[TBL] [Abstract][Full Text] [Related]
2. Restoration of growth hormone (GH) response to GH-releasing hormone in elderly and obese subjects by acute pharmacological reduction of plasma free fatty acids.
Pontiroli AE; Manzoni MF; Malighetti ME; Lanzi R
J Clin Endocrinol Metab; 1996 Nov; 81(11):3998-4001. PubMed ID: 8923850
[TBL] [Abstract][Full Text] [Related]
3. Acipimox Acutely Increases GLP-1 Concentrations in Overweight Subjects and Hypopituitary Patients.
Vestergaard ET; Hjelholt AJ; Kuhre RE; Møller N; Larraufie P; Gribble FM; Reimann F; Jessen N; Holst JJ; Jørgensen JOL
J Clin Endocrinol Metab; 2019 Jul; 104(7):2581-2592. PubMed ID: 30726969
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of lipolysis during acute GH exposure increases insulin sensitivity in previously untreated GH-deficient adults.
Segerlantz M; Bramnert M; Manhem P; Laurila E; Groop LC
Eur J Endocrinol; 2003 Dec; 149(6):511-9. PubMed ID: 14640991
[TBL] [Abstract][Full Text] [Related]
5. Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period.
Worm D; Henriksen JE; Vaag A; Thye-Rønn P; Melander A; Beck-Nielsen H
J Clin Endocrinol Metab; 1994 Mar; 78(3):717-21. PubMed ID: 8126147
[TBL] [Abstract][Full Text] [Related]
6. Long-term effects of a sustained-release preparation of acipimox on dyslipidemia and glucose metabolism in non-insulin-dependent diabetes mellitus.
Davoren PM; Kelly W; Gries FA; Hubinger A; Whately-Smith C; Alberti KG
Metabolism; 1998 Mar; 47(3):250-6. PubMed ID: 9500558
[TBL] [Abstract][Full Text] [Related]
7. Suppression of circulating free fatty acids with acipimox in chronic heart failure patients changes whole body metabolism but does not affect cardiac function.
Halbirk M; Nørrelund H; Møller N; Schmitz O; Gøtzsche L; Nielsen R; Nielsen-Kudsk JE; Nielsen SS; Nielsen TT; Eiskjær H; Bøtker HE; Wiggers H
Am J Physiol Heart Circ Physiol; 2010 Oct; 299(4):H1220-5. PubMed ID: 20709866
[TBL] [Abstract][Full Text] [Related]
8. Reducing plasma free fatty acids by acipimox improves glucose tolerance in high-fat fed mice.
Ahrén B
Acta Physiol Scand; 2001 Feb; 171(2):161-7. PubMed ID: 11350276
[TBL] [Abstract][Full Text] [Related]
9. Impact of Acipimox Therapy on Free Fatty Acid Efflux and Endothelial Function in the Metabolic Syndrome: A Randomized Trial.
Aday AW; Goldfine AB; Gregory JM; Beckman JA
Obesity (Silver Spring); 2019 Nov; 27(11):1812-1819. PubMed ID: 31571412
[TBL] [Abstract][Full Text] [Related]
10. The effect of long-term pharmacological antilipolysis on substrate metabolism in growth hormone (GH)-substituted GH-deficient adults.
Nielsen S; Møller N; Pedersen SB; Christiansen JS; Jørgensen JO
J Clin Endocrinol Metab; 2002 Jul; 87(7):3274-8. PubMed ID: 12107236
[TBL] [Abstract][Full Text] [Related]
11. Metabolic Effects of Long-Term Reduction in Free Fatty Acids With Acipimox in Obesity: A Randomized Trial.
Makimura H; Stanley TL; Suresh C; De Sousa-Coelho AL; Frontera WR; Syu S; Braun LR; Looby SE; Feldpausch MN; Torriani M; Lee H; Patti ME; Grinspoon SK
J Clin Endocrinol Metab; 2016 Mar; 101(3):1123-33. PubMed ID: 26691888
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological antilipolysis restores insulin sensitivity during growth hormone exposure.
Nielsen S; Møller N; Christiansen JS; Jørgensen JO
Diabetes; 2001 Oct; 50(10):2301-8. PubMed ID: 11574412
[TBL] [Abstract][Full Text] [Related]
13. Effect of acute pharmacological reduction of plasma free fatty acids on growth hormone (GH) releasing hormone-induced GH secretion in obese adults with and without hypopituitarism.
Cordido F; Fernandez T; Martinez T; Peñalva A; Peinó R; Casanueva FF; Dieguez C
J Clin Endocrinol Metab; 1998 Dec; 83(12):4350-4. PubMed ID: 9851776
[TBL] [Abstract][Full Text] [Related]
14. The nicotinic acid analogue acipimox increases plasma leptin and decreases free fatty acids in type 2 diabetic patients.
Worm D; Vinten J; Vaag A; Henriksen JE; Beck-Nielsen H
Eur J Endocrinol; 2000 Sep; 143(3):389-95. PubMed ID: 11022182
[TBL] [Abstract][Full Text] [Related]
15. Improved triglycerides and insulin sensitivity with 3 months of acipimox in human immunodeficiency virus-infected patients with hypertriglyceridemia.
Hadigan C; Liebau J; Torriani M; Andersen R; Grinspoon S
J Clin Endocrinol Metab; 2006 Nov; 91(11):4438-44. PubMed ID: 16940448
[TBL] [Abstract][Full Text] [Related]
16. Suppression of plasma free fatty acids reduces myocardial lipid content and systolic function in type 2 diabetes.
Wolf P; Winhofer Y; Krssak M; Smajis S; Harreiter J; Kosi-Trebotic L; Fürnsinn C; Anderwald CH; Baumgartner-Parzer S; Trattnig S; Luger A; Krebs M
Nutr Metab Cardiovasc Dis; 2016 May; 26(5):387-92. PubMed ID: 27118107
[TBL] [Abstract][Full Text] [Related]
17. Effect of acipimox, a lipid lowering drug, on growth hormone (GH) response to GH-releasing hormone in normal subjects.
Pontiroli AE; Lanzi R; Monti LD; Pozza G
J Endocrinol Invest; 1990 Jun; 13(6):539-42. PubMed ID: 2258583
[TBL] [Abstract][Full Text] [Related]
18. Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM.
Saloranta C; Taskinen MR; Widen E; Härkönen M; Melander A; Groop L
Diabetes; 1993 Nov; 42(11):1559-66. PubMed ID: 8405695
[TBL] [Abstract][Full Text] [Related]
19. Effects of prolonged fasting and sustained lipolysis on insulin secretion and insulin sensitivity in normal subjects.
Salgin B; Marcovecchio ML; Humphreys SM; Hill N; Chassin LJ; Lunn DJ; Hovorka R; Dunger DB
Am J Physiol Endocrinol Metab; 2009 Mar; 296(3):E454-61. PubMed ID: 19106250
[TBL] [Abstract][Full Text] [Related]
20. Different acute and chronic effects of acipimox treatment on glucose and lipid metabolism in patients with type 2 diabetes.
Saloranta C; Groop L; Ekstrand A; Franssila-Kallunki A; Eriksson J; Taskinen MR
Diabet Med; 1993 Dec; 10(10):950-7. PubMed ID: 8306591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
